Prestige Consumer Healthcare Inc. (PBH): Operating Cash Flow
$257.63M
Year ended 2026-03-31
$249.40M
Trailing 12 months to 2026-06-30
+3.9%
3-year compound annual growth
+1.8%
5-year compound annual growth
+3.9%
10-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $257.63M | +2.4% | 2026-05-14, From 2025-04-01 |
| 2025-03-31 | $251.51M | +1.0% | 2026-05-14, From 2024-04-01 |
| 2024-03-31 | $248.93M | +8.4% | 2026-05-14, From 2023-04-01 |
| 2023-03-31 | $229.72M | -11.6% | 2025-05-09, From 2022-04-01 |
| 2022-03-31 | $259.92M | +10.3% | 2024-05-15, From 2021-04-01 |
| 2021-03-31 | $235.61M | +8.5% | 2023-05-05, From 2020-04-01 |
| 2020-03-31 | $217.12M | +14.7% | 2022-05-06, From 2019-04-01 |
| 2019-03-31 | $189.28M | -9.9% | 2021-05-07, From 2018-04-01 |
| 2018-03-31 | $210.11M | +41.3% | 2020-05-08, From 2017-04-01 |
| 2017-03-31 | $148.67M | -15.7% | 2019-05-13, From 2016-04-01 |
| 2016-03-31 | $176.31M | n/c | 2018-05-10, From 2015-04-01 |
| 2015-03-31 | $156.25M | +40.0% | 2017-05-17, From 2014-04-01 |
| 2014-03-31 | $111.58M | -18.9% | 2016-05-17, From 2013-04-01 |
| 2013-03-31 | $137.60M | +104.0% | 2015-05-14, From 2012-04-01 |
| 2012-03-31 | $67.45M | -22.2% | 2014-05-19, From 2011-04-01 |
| 2011-03-31 | $86.67M | +45.8% | 2013-05-17, From 2010-04-01 |
| 2010-03-31 | $59.43M | n/a | 2012-05-18, From 2009-04-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $257.63M | +2.4% |
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $109.84M | -30.4% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | -$189.55M | n/m |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | -$27.00M | n/m |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | -$268.58M | n/m |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $185.22M | +189.3% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $348.20M | +58.4% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $179.55M | n/m |
| Alkermes plc. (ALKS) | 2025-12-31 | $520.75M | +18.6% |
Compare PBH, ACAD, MDGL, INDV side by side · Screen every company in Pharmaceutical Preparations ↗